Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study
Authors
Frank Richard (ORCID: https://orcid.org/0000-0003-1027-3814)
Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study
Frank Richard, Carina Levin, John B. Porter, Ricardo Hermosilla et al.
Journal
Orphanet Journal of Rare Diseases
Topics
Hemoglobinopathies and Related Disorders
article
Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study
Frank Richard, Carina Levin, John B. Porter, Ricardo Hermosilla, Antonis Kattamis, Maria Domenica Cappellini, Alì Taher, Vip Viprakasit, Peter Szecsödy
article en
Abstract
No abstract available for this paper.
Publication Tag
Orphanet Journal of Rare DiseasesVol. 20(1)
Institutions
Siriraj Hospital (TH), Technion – Israel Institute of Technology (IL), National and Kapodistrian University of Athens (GR), Mahidol University (TH), Emek Medical Center (IL), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Vifor Pharma (Switzerland) (CH), American University of Beirut Medical Center (LB), Heidelberg Pharma (Germany) (DE), Iaso Children’s Hospital (GR), University College London (GB), CSL (Switzerland) (CH)
Funders
CSL Behring, University of Patras, Chiang Mai University, Naresuan University